VA awards $2.5M for Lenalidomide Capsules to Exelan Pharmaceuticals Inc
Contract Overview
Contract Amount: $2,534,077 ($2.5M)
Contractor: Exelan Pharmaceuticals Inc
Awarding Agency: Department of Veterans Affairs
Start Date: 2026-01-16
End Date: 2027-01-15
Contract Duration: 364 days
Daily Burn Rate: $7.0K/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 1
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: LENALIDOMIDE CAPSULES.
Place of Performance
Location: CARY, WAKE County, NORTH CAROLINA, 27513
Plain-Language Summary
Department of Veterans Affairs obligated $2.5 million to EXELAN PHARMACEUTICALS INC for work described as: LENALIDOMIDE CAPSULES. Key points: 1. The Department of Veterans Affairs (VA) is procuring Lenalidomide Capsules. 2. Exelan Pharmaceuticals Inc. is the awardee. 3. The contract is for a 364-day period. 4. This is a firm-fixed-price contract. 5. The award was made under full and open competition.
Value Assessment
Rating: good
The contract value of $2,534,076.50 for 364 days of Lenalidomide Capsules appears reasonable given the nature of pharmaceutical procurement. Benchmarking against similar contracts for specialized medications would provide a more precise assessment.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, suggesting a competitive bidding process. This method is expected to yield fair market prices and ensure value for taxpayer money.
Taxpayer Impact: The competitive award process aims to secure the best possible price for these essential medications, maximizing the value of taxpayer funds.
Public Impact
Veterans will have continued access to Lenalidomide Capsules, a critical medication. The procurement ensures a stable supply chain for this pharmaceutical product. The VA's commitment to competitive bidding benefits the healthcare system.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Positive Signals
- Full and open competition utilized
- Clear contract duration and delivery schedule
- Firm fixed price contract type
Sector Analysis
The pharmaceutical preparation manufacturing sector is highly regulated and competitive. Spending on specialized drugs like Lenalidomide is significant within the healthcare sector, driven by medical necessity and drug development costs.
Small Business Impact
There is no indication that small businesses were involved in this specific contract award, as the data does not specify subcontracting opportunities or prime awardee size.
Oversight & Accountability
The Department of Veterans Affairs is responsible for overseeing this contract to ensure timely delivery and adherence to quality standards. The firm-fixed-price structure provides cost certainty.
Related Government Programs
- Pharmaceutical Preparation Manufacturing
- Department of Veterans Affairs Contracting
- Department of Veterans Affairs Programs
Risk Flags
- Potential for price increases in future contract periods
- Dependence on a single supplier for a critical medication
- Lack of detailed cost breakdown in the provided data
Tags
pharmaceutical-preparation-manufacturing, department-of-veterans-affairs, nc, delivery-order, 1m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Veterans Affairs awarded $2.5 million to EXELAN PHARMACEUTICALS INC. LENALIDOMIDE CAPSULES.
Who is the contractor on this award?
The obligated recipient is EXELAN PHARMACEUTICALS INC.
Which agency awarded this contract?
Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).
What is the total obligated amount?
The obligated amount is $2.5 million.
What is the period of performance?
Start: 2026-01-16. End: 2027-01-15.
What is the historical pricing trend for Lenalidomide Capsules procured by the VA or other federal agencies?
Analyzing historical pricing data for Lenalidomide Capsules is crucial for a comprehensive value assessment. Understanding past price fluctuations, bulk purchase discounts, and the impact of generic availability can reveal whether the current award represents a favorable price point. This context helps determine if the VA is achieving cost efficiencies or if there are opportunities for further negotiation or alternative sourcing strategies.
What are the specific therapeutic uses and patient population served by Lenalidomide Capsules within the VA system?
Lenalidomide is primarily used to treat multiple myeloma and certain other blood disorders. Understanding the specific patient population and the critical nature of these treatments within the VA system helps contextualize the spending. High demand for life-saving or life-extending medications can influence price sensitivity and the urgency of procurement, impacting the negotiation leverage.
Are there any known supply chain risks or single points of failure associated with Exelan Pharmaceuticals Inc. or the manufacturing of Lenalidomide?
Assessing supply chain risks is vital, especially for critical medications. Investigating Exelan Pharmaceuticals Inc.'s manufacturing capacity, regulatory compliance history, and any potential dependencies on raw material suppliers can identify vulnerabilities. Understanding these risks helps the VA implement mitigation strategies, such as requiring backup suppliers or maintaining strategic reserves, to ensure uninterrupted patient access.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing
Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY
Offers Received: 1
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Address: 370 W CAMINO GARDENS BLVD STE 204, BOCA RATON, FL, 33432
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Not Designated a Small Business, Special Designations
Financial Breakdown
Contract Ceiling: $2,534,077
Exercised Options: $2,534,077
Current Obligation: $2,534,077
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Parent Contract
Parent Award PIID: 36F79720D0227
IDV Type: FSS
Timeline
Start Date: 2026-01-16
Current End Date: 2027-01-15
Potential End Date: 2027-01-15 00:00:00
Last Modified: 2026-01-16
More Contracts from Exelan Pharmaceuticals Inc
- Oseltamivir Phosphate 75MG Capsules (NDC: 76282-0704-45); 10 CT. Blisters Packs and Oseltamivir Phosphate 30MG Capsules (NDC: 76282-0702-45); 10 CT. Blisters Packs — $74.1M (Department of Health and Human Services)
- Lenalidomide for the Salisbury Vamc, Charlotte HCC, and Kernersville HCC — $5.1M (Department of Veterans Affairs)
- Lenalidomide for the Durham Vamc for Patient Care — $4.5M (Department of Veterans Affairs)
- Lenalidomide for the Richmond Vamc for Patient Care — $4.1M (Department of Veterans Affairs)
- VA Long Beach Lenalidomide DO — $3.7M (Department of Veterans Affairs)
Other Department of Veterans Affairs Contracts
- CCN Region 3 Express Report — $5.2B (Optum Public Sector Solutions, Inc.)
- Express Report for FY22 Region 2 — $5.1B (Optum Public Sector Solutions, Inc.)
- Fiscal Year 2022 Express Report for Region 1 — $4.2B (Optum Public Sector Solutions, Inc.)
- Express Report for the Patient Centered Community Care (PC3) Contract — $3.3B (Triwest Healthcare Alliance Corp)
- CCN Region Three FY21 Express Report — $3.1B (Optum Public Sector Solutions, Inc.)